Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick E H Jackson

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Open Forum Infectious Diseases|April 25, 2024
Machine Learning-based Analysis of Publications Funded by the National Institutes of Health's Initial COVID-19 Pandemic ResponseAnirudha S Chandrabhatla, Adishesh K Narahari, Taylor M Horgan, et al.
Open Forum Infectious Diseases|March 27, 2024
Analysis of National Institutes of Health Funding for the COVID-19 PandemicAdishesh K Narahari, Taylor M Horgan, Anirudha S Chandrabhatla, et al.
Medrxiv : the Preprint Server for Health Sciences|April 12, 2022
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa TrialJennifer Sasson, Alexandra N Donlan, Jennie Z Ma, et al.
Open Forum Infectious Diseases|August 12, 2022
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a TrialJennifer Sasson, Alexandra N Donlan, Jennie Z Ma, et al.
Science Immunology|February 23, 2023
Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19Bibo Zhu, Xiaoqin Wei, Harish Narasimhan, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Open Forum Infectious Diseases|April 25, 2024
Machine Learning-based Analysis of Publications Funded by the National Institutes of Health's Initial COVID-19 Pandemic ResponseAnirudha S Chandrabhatla, Adishesh K Narahari, Taylor M Horgan, et al.
Open Forum Infectious Diseases|March 27, 2024
Analysis of National Institutes of Health Funding for the COVID-19 PandemicAdishesh K Narahari, Taylor M Horgan, Anirudha S Chandrabhatla, et al.
Medrxiv : the Preprint Server for Health Sciences|April 12, 2022
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa TrialJennifer Sasson, Alexandra N Donlan, Jennie Z Ma, et al.
Open Forum Infectious Diseases|August 12, 2022
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a TrialJennifer Sasson, Alexandra N Donlan, Jennie Z Ma, et al.
Science Immunology|February 23, 2023
Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19Bibo Zhu, Xiaoqin Wei, Harish Narasimhan, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
Pageof 2